Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Yamanouchi discloses 5-HT2C receptor agonists with high potency and selectivity

Oct. 27, 1998

Korean research institute develops new NMDA receptor antagonists

Oct. 27, 1998

Agents for schizophrenia from Yoshitomi typified by Y-36074

Oct. 27, 1998

Dainippon will initiate European development of antipsychotic drug candidate

Oct. 27, 1998

Sublingual apomorphine safe and effective in PD patients with motor fluctuations

Oct. 26, 1998

Transdermal selegiline as monotherapy in mild to moderate Parkinson's disease

Oct. 26, 1998

Transdermal D2 agonist therapy with N-0923 safe and effective in PD

Oct. 26, 1998

Metabasis Therapeutics seeks partner for development of anticonvulsant

Oct. 26, 1998

Safe and effective therapeutics for neuropathic pain in early development at Roche

Oct. 26, 1998

Roche granted additional exclusivity for Versed from FDA

Oct. 23, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...